Investigational Drug Information for MT-1303
✉ Email this page to a colleague
What is the development status for investigational drug MT-1303?
MT-1303 is an investigational drug.
There have been 12 clinical trials for MT-1303.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, and Crohn Disease. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Corporation, Bausch Health Americas, Inc., and [disabled in preview].
Summary for MT-1303
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 31 |
Recent Clinical Trials for MT-1303
| Title | Sponsor | Phase |
|---|---|---|
| Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis | Bausch Health Americas, Inc. | Phase 2 |
| Extension Study of MT-1303 in Subjects With Crohn's Disease | Mitsubishi Tanabe Pharma Corporation | Phase 2 |
| Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease | Mitsubishi Tanabe Pharma Corporation | Phase 2 |
Clinical Trial Summary for MT-1303
Top disease conditions for MT-1303
Top clinical trial sponsors for MT-1303
US Patents for MT-1303
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
